Jiashan Manufacturing Site

In March 2020, Everest formed a strategic partnership with Jiashan National Economic and Technological Development Zone in Zhejiang province and Jiashan SDIC to build its global manufacturing site in the Jiashan National Economic and Technological Development Zone. The project was listed as one of the 65 major projects in the Yangtze River Delta Integration Demonstration Zone. In Nov. 2020, Everest started construction at the facility.

In Dec. 2022, the first phase of the global manufacturing site dedicated to mRNA vaccine production initiated operations and successfully carried out trial production runs. The first phase of the project, covering an area of 58,000 square meters and with an investment of more than RMB 900 million, is designed with an annual production capacity of 700 million doses of mRNA vaccines. The project is designed to be in full compliance with NMPA, EMA GMP, and WHO PQ standards, and is expected to meet both domestic and international demand for high quality mRNA vaccines.

By localizing our clinically validated and advanced mRNA technology platform, Everest takes a key step in our strategic goal of having a complete industrial value chain of research and discovery, clinical development, manufacturing and commercialization. The company is developing therapeutic vaccines such as cancer vaccines and several of its mRNA cancer vaccines are expected to enter clinical trials in 2024 and 2025.